Tecan's Transformation Takes Hold: Above-Market Growth and a New Strategic Direction

The CHF 1B sales target and 20% margin goal rest on 'Rewired' execution and an AI-forward portfolio, but management keeps a cautious eye on market recovery.

TECN.SW · Earnings Call · 2026-08-11

Rewired: From Promise to Early Proof

Tecan's first-half 2026 results mark a turning point. The company grew 3.4% in local currencies, outpacing its end markets, while holding adjusted EBITDA margin at 15.1%. More importantly, the Rewired program — the three-year transformation launched in Q1 — is already showing tangible results. “I am pleased to say that our solid results with above-market growth in the first half gives us good reason for confidence.” — Monica Manotas, Chief Executive Officer · 2026-08-11 The program is designed to generate >4% CAGR and deliver CHF 1B sales at a 20% adjusted EBITDA margin by 2028. Early savings are coming from portfolio exits and operational improvements, but CFO Camila Japur is keeping a tight rein: “My focus in the coming months will be on establishing disciplined cost base tracking and developing a comprehensive understanding of all underlying cost drivers.” — Camila Japur, Chief Financial Officer · 2026-08-11 That emphasis on the cost base is new; the previous leadership talked about cost measures, but not with this level of structural intent.

AI and the Autonomous Lab Opportunity

The bigger strategic pivot is AI. Tecan's NVIDIA partnership and the launch of AI features for its Introspect software signal a shift toward autonomous labs. Customer conversations are now centered on how automation and AI can close the loop between in-silico discovery and wet-lab validation.

This is a really, really exciting topic for us... certainly, we see it on the side of the opportunity of how automation can play a role and just seeing the excitement from a customers' perspective.
Monica Manotas, Chief Executive Officer · 2026-08-11

This is a marked departure from earlier calls, where AI was mentioned only peripherally. The company is also building a biofoundry in Japan and expanding in India — concrete steps toward making AI-powered labs a commercial reality.

Prudent on the Market, Confident on Execution

Despite the optimism, management remains wary of the pace of market recovery. "We believe it is too early to call a change in trend," Manotas said, even as order entry held above 1.0x book-to-bill. This caution echoes prior quarters: a year ago, she told investors “it's a little bit too early... to understand better our position in the various areas of the business.” — Monica Manotas, Chief Executive Officer · 2025-08-12 And in March 2025, the former CEO described China's downturn as a "revenue envelope" of cutbacks: “In China, we ended China last year at a revenue envelope of around CHF 100 million.” — Achim von Leoprechting, Chief Executive Officer · 2025-03-12 The difference now is that Tecan has a lever to pull: order growth is above market, and the company says it will likely close the year at the upper end of its guided margin range. “We expect to be more in the upper range of that guidance.” — Camila Japur, Chief Financial Officer · 2026-08-11 Camila Japur noted, though she declined to change the official range pending a deeper review of costs. The stock is still digesting the news, but the narrative has shifted. Tecan is no longer just a turnaround story; it's a company with a clear plan to ride AI and automation tailwinds — if the market cooperates.